352 related articles for article (PubMed ID: 24380613)
1. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
[TBL] [Abstract][Full Text] [Related]
2. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
3. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
[TBL] [Abstract][Full Text] [Related]
4. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
5. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
6. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
7. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
[TBL] [Abstract][Full Text] [Related]
9. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Ranalletta M; Bierilo KK; Chen Y; Milot D; Chen Q; Tung E; Houde C; Elowe NH; Garcia-Calvo M; Porter G; Eveland S; Frantz-Wattley B; Kavana M; Addona G; Sinclair P; Sparrow C; O'Neill EA; Koblan KS; Sitlani A; Hubbard B; Fisher TS
J Lipid Res; 2010 Sep; 51(9):2739-52. PubMed ID: 20458119
[TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
12. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
[TBL] [Abstract][Full Text] [Related]
13. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
Forrest MJ; Bloomfield D; Briscoe RJ; Brown PN; Cumiskey AM; Ehrhart J; Hershey JC; Keller WJ; Ma X; McPherson HE; Messina E; Peterson LB; Sharif-Rodriguez W; Siegl PK; Sinclair PJ; Sparrow CP; Stevenson AS; Sun SY; Tsai C; Vargas H; Walker M; West SH; White V; Woltmann RF
Br J Pharmacol; 2008 Aug; 154(7):1465-73. PubMed ID: 18536749
[TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Rios FJ; Neves KB; Nguyen Dinh Cat A; Even S; Palacios R; Montezano AC; Touyz RM
J Pharmacol Exp Ther; 2015 Apr; 353(1):27-34. PubMed ID: 25617244
[TBL] [Abstract][Full Text] [Related]
15. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
Cao G; Beyer TP; Zhang Y; Schmidt RJ; Chen YQ; Cockerham SL; Zimmerman KM; Karathanasis SK; Cannady EA; Fields T; Mantlo NB
J Lipid Res; 2011 Dec; 52(12):2169-2176. PubMed ID: 21957197
[TBL] [Abstract][Full Text] [Related]
16. Safety of CETP inhibition.
Duivenvoorden R; Fayad ZA
Curr Opin Lipidol; 2012 Dec; 23(6):518-24. PubMed ID: 23010697
[TBL] [Abstract][Full Text] [Related]
17. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Sirtori CR
Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Filippatos TD; Klouras E; Barkas F; Elisaf M
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
[TBL] [Abstract][Full Text] [Related]
20. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
Qiao JX; Wang TC; Adam LP; Chen AY; Taylor DS; Yang RZ; Zhuang S; Sleph PG; Li JP; Li D; Yin X; Chang M; Chen XQ; Shen H; Li J; Smith D; Wu DR; Leith L; Harikrishnan LS; Kamau MG; Miller MM; Bilder D; Rampulla R; Li YX; Xu C; Lawrence RM; Poss MA; Levesque P; Gordon DA; Huang CS; Finlay HJ; Wexler RR; Salvati ME
J Med Chem; 2015 Nov; 58(22):9010-26. PubMed ID: 26524347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
